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COPD 2020 Guidelines — what is new and why?
To the editor
The new year dawns with new guidelines. 
Global Initiative for Obstructive Lung Disease 
(GOLD 2020) has some major and few minor 
changes to offer for the management of COPD. 
The significant changes include defining the role 
of inhaled corticosteroids (ICS) and vitamin D 
levels [1].
Definition — the definition remains the same. 
“Chronic Obstructive Pulmonary Disease (COPD) 
is a common, preventable, and treatable disease 
that is characterized by persistent respiratory 
symptoms and airflow limitation that is due to 
airway and/or alveolar abnormalities usually 
caused by significant exposure to noxious partic-
les or gases”. However, there may be significant 
lung pathology (emphysema) in the absence of 
airflow obstruction, which warrants a detailed 
assessment. This stems from the ancient concept 
of GOLD 0, where there were structural changes 
but no obstruction. Being a clinically common 
scenario, the entity of emphysema without obs-
truction has been re-introduced.
Epidemiology — the predicted mortality by 
2030 of 4.5 million deaths annually from COPD 
and related conditions has been extrapolated to 
over 5.4 million deaths annually by 2060 [2]. 
Among risk factors, documented Pseudomonas 
infection is a  new addition. The rationale is 
a  large observational study which documented 
that Pseudomonas aeruginosa colonization inde-
pendently predicted an increased risk of hospita-
lization for exacerbation and all-cause mortality 
[3]. The utility of biomarkers in COPD has a new 
comment. The guidelines advocate the use of se-
rum C-reactive protein (CRP) and procalcitonin in 
restricting antibiotic usage during exacerbations 
[1]. However, the observed sputum color remains 
highly sensitive and specific for a high bacterial 
load during such episodes. The SUMMIT trial 
failed to show the benefit of using CRP, SPD, 
s RAGE, CC-16, and fibrinogen to predict forced 
expiratory volume in 1st second (FEV1) decline, 
hospitalization, or exacerbation [4]. Continued 
cautious and realistic interpretation of the role 
of biomarkers in the management of identified 
clinical traits is needed. 
A caution on the use of e-cigarettes has been 
mentioned in the new guidelines citing a lack of 
safety data. Eosinophilic pneumonias, acute lung 
injury, diffuse alveolar hemorrhage and respirato-
ry bronchiolitis have been linked to their use [5]. 
The CDC and FDA are investigating this, around 
1604 illnesses and 34 deaths have been reported 
up to October 2019. Certain countries including 
India have recently banned the use of e-cigarettes 
citing unproven safety profile.
Diagnosis and treatment plan — the treat-
ment algorithm emphasizes on using the ABCD 
assessment to determine initial treatment only. 
The follow-up treatment utilizes the management 
cycle changes as per dyspnea or exacerbation, 
similar to 2019 guidelines. The management 
of persistent dyspnoea with add-on bronchodi-
lators and recurrent exacerbation with add-on 
inhaled steroids is identical to the GOLD 2019 
guidelines [1].
The role of inhaled steroids (ICS) in the 
GOLD 2020 guidelines has been clarified. The 
history of ≥ 2 moderate exacerbations or hospi-
talization(s) attributable to exacerbation, serum 
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eosinophilia (> 300 cells/µL) or concomitant 
asthma are factors that strongly support the use 
of ICS. The factors unfavorable to ICS use are 
recurrent pneumonia, history of mycobacterial 
infection, and eosinophils (<100 cells/µL) [6]. 
The new guidelines do mention that recent trials 
using triple therapy, showing a mortality benefit. 
However, as mortality was not the primary end-
point of any of the studies, hence, the mortality 
benefit warrants further evaluation [6, 7].
GOLD 2020 guidelines recommend all pa-
tients hospitalized for exacerbations should be 
assessed and investigated for the severe Vitamin 
D deficiency (< 10 ng/mL or < 25 nM), followed 
by supplementation if required. The rationale is 
similar to all chronic diseases; vitamin D levels 
are lower in COPD than in health. A recent meta-
-analysis showed that vitamin D supplementation 
reduced exacerbation rates in patients with low 
baseline vitamin D levels [8]. However, in unse-
lected patients, the decline is not documented. 
Theophylline use in COPD has an unchanged 
recommendation. A trial in 2018, using low dose 
theophylline found no benefit in reducing exa-
cerbation rates, and hence efficacy for the same 
remains doubtful [9].
The guidelines draw on the importance of 
phenotyping COPD patients. Four phase 3 stu-
dies evaluated the efficacy of mepolizumab and 
benralizumab in patients with severe COPD. The 
inclusion criteria were recurrent exacerbations 
and peripheral blood evidence of eosinophilic 
inflammation despite high intensity inhaled the-
rapy. There was a 15–20% reduction in the rate of 
severe exacerbations, but, it was variable between 
studies and doses. There was no effect on FEV1 
or quality of life scores and no consistent rela-
tionship between the response to treatment and 
the peripheral blood eosinophil count. A posthoc 
analysis of the mepolizumab trial showed a more 
significant benefit against oral corticosteroid 
treated exacerbations [10, 11]. Thus, raising the 
possibility of this treatment might gain a  role 
in a highly selected subgroup of patients with 
eosinophilic COPD and frequent requirement for 
oral corticosteroids. Further studies are required 
to investigate this.
Non-medical management — interventional 
procedures like endobronchial valves recom-
mended according to appropriate indication. 
The rationale stemmed from the EMPROVE trial 
reporting a significant benefit in FEV1, hyperinfla-
tion, dyspnoea, and health status [12]. However, 
the possibility of considerable pneumothorax 
warrants the need for the procedure performed at 
expert centers only. The current guidelines docu-
ment the additional role of pulmonary rehabilita-
tion in the reduction of anxiety and depression. 
Acute exacerbation — the classification and 
management protocol of acute exacerbation epi-
sodes is unchanged. The clinical suspicion and 
investigative workup of the differential diagnosis 
of an exacerbation are listed in present guidelines. 
Thus, stress on systemic disease evaluation and 
comorbidities in diagnosis are explicit. 
Clinical impact and future directives — the 
GOLD 2020 document presents a global resour-
ce as an evidence-based review and guide for 
the diagnosis, management, and prevention of 
COPD. The importance of COPD is magnified by 
the increasing global burden of this disease with 
estimated increased mortality by 2060. The new 
guidelines recognize the role of ICS as an indivi-
dualized decision with a detailed evaluation of 
risks and benefits. The position of triple inhaled 
therapy, biologics, lung volume reduction, need 
for biomarkers, and assessment of vitamin D de-
ficiency have been explicitly stated. Even though 
these differences are subtle, they provide the 
future directive of research.
Certain limitations include the specification 
that persistent symptoms are required to make the 
diagnosis which leaves outpatients with varying 
day-to-day traits. Additional updates regarding no-
vel pharmacotherapeutic options, asthma-COPD 
overlap phenotype, recommendations around 
e-cigarette use, and further guidance for referral 
for lung transplantation are the need of the future.
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